Bloodborne microparticles are submicron vesicles released from cells within the vascular compartment. Pathologic alterations of microparticle populations have been explored in a large number of conditions ranging from multiple sclerosis to dengue fever.[1, 2] Despite wide ranging interest in the field of microparticles and their potential as biomarkers for disease states, their use in clinical practice is essentially nonexistent. A number of obstacles thus far have prohibited the translation of published observations into more generalizable clinical applications, not the least of which remains a lack of consensus regarding appropriate methodology for the measurement of microparticles. This article is protected by copyright. All rights reserved.